Sodium Zirconium Cyclosilicate
Drugs For Treatment Of Hyperkalemia and Hyperphosphatemia
Sold as Lokelma
- Drug class
- Drugs For Treatment Of Hyperkalemia and Hyperphosphatemia
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 11
Overview
Sodium Zirconium Cyclosilicate is an active pharmaceutical ingredient in the Drugs For Treatment Of Hyperkalemia and Hyperphosphatemia group (V03AE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| EU European Union | EMA | 1 | September 3, 2025 |
| GB United Kingdom | MHRA | 8 | April 10, 2026 |
| CA Canada | Health Canada | 2 | April 23, 2026 |
EUEuropean Union· EMA
1 product
Uses
1).
How to take
GBUnited Kingdom· MHRA
8 products
8 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Sodium Zirconium Cyclosilicate. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]European Medicines Agency · EMEA/H/C/004029 · revised September 3, 2025
- [2]MHRA (UK) · PLPI206363358 · revised September 19, 2025
- [3]Health Canada (DPD) · 02490714 · revised April 23, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.